Entera Bio Ltd. EBT margin

EBT margin of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including EBT margin growth rates and interactive chart. The Earnings before tax margin. Calculated as earnings before tax divided by revenue. Measures the profitability of a company after all expenses are paid but before taxes. This is useful to compare various companies in an industry that might have different tax regimes or tax rates.


Highlights and Quick Summary

  • EBT margin for the quarter ending June 29, 2020 was -6134.62% (a -11.7% decrease compared to previous quarter)
  • Year-over-year quarterly EBT margin increased by 22.94%
  • Annual EBT margin for 2019 was -4574.15% (a 121.96% increase from previous year)
  • Annual EBT margin for 2018 was -2060.8% (a -Infinity% decrease from previous year)
  • Twelve month EBT margin ending June 29, 2020 was -4899.22% (a 27.07% increase compared to previous quarter)
  • Twelve month trailing EBT margin decreased by -Infinity% year-over-year
Trailing EBT margin for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
-4899.22% -3855.4% -1466.71% 0.0%
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EBT margin of Entera Bio Ltd.

Most recent EBT marginof ENTX including historical data for past 10 years.

Interactive Chart of EBT margin of Entera Bio Ltd.

Entera Bio Ltd. EBT margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 -6134.62% -6947.62%
2019 -3372.55% -4990.0% -1845.95% 0.0% -4574.15%
2018 -529.0% 0.0% 0.0% 0.0% -2060.8%
2017 0.0%

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.